Kadimastem Ltd
KDST
Rang in Aktien
#40943
Kadimastem Ltd is a biopharmaceutical company focused on pioneering... Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. Additionally, the company is advancing IsletRx, a clinical-grade pancreatic islet cell therapy intended for the treatment of diabetes. Incorporated in 2008, Kadimastem is headquartered in Ness Ziona, Israel.
Aktienkurs
$12.16
Zuletzt synchronisiert: 2025-10-30
Marktkapitalisierung
$50.98K
Veränderung (1 Tag)
-0.10%
Veränderung (1 Jahr)
69.56%
Land
IL
Handel Kadimastem Ltd (KDST)
Kategorie
Healthcare
Kursverlauf für Kadimastem Ltd (KDST)
Höchster Schlusskurs: $3.43 am 2025-12-01
Niedrigster Schlusskurs: $8.68 am 2021-01-01
Niedrigster Schlusskurs: $8.68 am 2021-01-01
Kursverlauf der Aktie von Kadimastem Ltd von 2021 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 29.04% |
| 2025 | -62.21% |
| 2024 | -1.52% |
| 2023 | 0.00% |
| 2022 | -67.49% |
| 2021 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
